Progress of immunotherapy for NK/T cell leukemia/lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 565-569, 2023.
Article
ي Zh
| WPRIM
| ID: wpr-1017356
المكتبة المسؤولة:
WPRO
ABSTRACT
NK/T cell leukemia/lymphoma is a type of malignancy originating from T cells or natural killer cells with low incidence and poor clinical prognosis. There is still no effective treatment strategy. In recent years, targeted therapy has made great progress in the treatment of hematological malignancies, including monoclonal antibody and chimeric antigen receptor T cells (CAR-T), among which CD30, CD7, CD5, CD52, CCR4 and other target antigens are effective in the treatment of NK/T cell leukemia/lymphoma, but its widespread application still faces a great challenge. This article reviews the progress of immunotherapy for NK/T cell leukemia/lymphoma.
النص الكامل:
1
الفهرس:
WPRIM
اللغة:
Zh
مجلة:
Journal of Leukemia & Lymphoma
السنة:
2023
نوع:
Article